Media Library

While everyone agrees that better access to medicines is important, the challenge with using the regulatory framework to achieve this objective is that it's not the right tool for the task.

View of the Novartis logo through the colorful facade of Forum 3, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (horizontal)

Close up of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building from Park South, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building from the main gate, Novartis Campus Basel (vertical)

View of the Novartis logo on the Banting 1 building, Novartis Campus Basel (vertical)

Long-term assessment of the efficacy and safety of inclisiran in patients with high risk of cardiovascular events

Cardiovascular disease (CVD) is the leading cause of death worldwide. Investment in heart health has declined for decades.

A dynamic clinical trial program co-created with healthcare partners worldwide to generate evidence on the impact of cholesterol lowering with Leqvio® (Inclisiran).

Chief Corporate Affairs Officer